XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:        
Revenue from collaborative arrangements and other contracts $ 388,446 $ 9,154,133 $ 729,359 $ 10,137,602
Operating expenses:        
Research and development 15,503,032 33,087,130 69,423,513 145,530,626
General and administrative 9,925,055 11,824,047 37,338,763 76,234,341
Impairment of goodwill 10,513,371 0 10,513,371 0
Total operating expenses 35,941,458 44,911,177 117,275,647 221,764,967
Loss from operations (35,553,012) (35,757,044) (116,546,288) (211,627,365)
Other income (expense):        
Interest income 1,938,745 1,365,759 6,314,149 2,893,240
Interest expense (313,488) (313,488) (940,464) (940,464)
Gain (loss) on investment in affiliated entity 214,374 (305,061) 987,758 (1,776,804)
Net unrealized gain (loss) on available-for-sale equity securities (219,337) (1,833,284) 3,921,819 (10,641,026)
Other income (expense), net 2,854 (940,778) (3,850,688) (1,097,294)
Net loss before share in net loss of Geneos (33,929,864) (37,783,896) (110,113,714) (223,189,713)
Share in net loss of Geneos 0 0 0 (2,165,213)
Net loss $ (33,929,864) $ (37,783,896) $ (110,113,714) $ (225,354,926)
Net loss per share        
Basic (in dollars per share) $ (0.13) $ (0.15) $ (0.42) $ (0.96)
Diluted (in dollars per share) $ (0.13) $ (0.15) $ (0.42) $ (0.96)
Weighted average number of common shares outstanding        
Basic (in shares) 268,622,753 249,351,023 263,842,074 234,634,724
Diluted (in shares) 268,622,753 249,351,023 263,842,074 234,634,724